目的:探讨硝苯地平联合厄贝沙坦治疗2型糖尿病合并高血压的临床疗效与安全性。方法:将80例T2DM合并高血压患者随机均分为对照组与治疗组,对照组使用硝苯地平片进行治疗,治疗组在此基础上联合使用厄贝沙坦进行治疗。比较治疗前后血压(SBP与DBP)、空腹血糖、餐后2h血糖水平变化差异及不良反应发生情况。结果:(1)两组患者治疗后SBP及DBP水平均较治疗前显著降低(P<0.05),且治疗组治疗后SBP及DBP水平均显著低于对照组治疗后(P<0.05);(2)对照组治疗前后空腹血糖、餐后2h血糖水平变化无统计学差异(P>0.05),但治疗组治疗前后血糖水平差异具有统计学意义(P<0.05);(3)对照组不良反应发生率为10.00%,治疗组为7.50%,二者差异无统计学意义(P>0.05)。结论:硝苯地平联合厄贝沙坦治疗T2DM合并高血压的疗效显著,不良反应发生率低,应进行推广。 Objective: To investigate the clinical efficacy and safety of nifedipine combined with irbesartan in the treatment of type 2 diabetes mellitus complicated with hypertension. Methods: Eighty patients with T2DM and hypertension were randomly divided into control group and treatment group. The control group was treated with nifedipine tablets. The treatment group was treated with irbesartan on this basis. Blood pressure (SBP and DBP), fasting blood glucose, postprandial 2h blood glucose levels and adverse reactions were compared before and after treatment. Results: (1) SBP and DBP levels in both groups after treatment were significantly lower than those before treatment (P <0.05), and SBP and DBP levels in the treatment group were significantly lower than those in the control group after treatment (P <0.05); ( (2) There was no significant difference in fasting blood glucose before and after treatment between two groups (P> 0.05), but there was significant difference in blood glucose before and after treatment in the treatment group (P <0.05); (3) adverse reactions in the control group The incidence was 10.00%, and the treatment group was 7.50%. There was no significant difference between the two groups (P> 0.05). Conclusion: Nifedipine combined with irbesartan in the treatment of T2DM with hypertension has significant curative effect and low incidence of adverse reactions and should be promoted.